The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1535
ISSUE 1535
December 4, 2017
Issue 1535
- Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine
- Naldemedine (Symproic) for Opioid-Induced Constipation
- Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease
- PARP Inhibitors for Ovarian Cancer
- In Brief: New Hypertension Guidelines
- Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine
December 4, 2017 (Issue: 1535)
The FDA has approved an adjuvanted, recombinant
varicella zoster virus (VZV) vaccine (Shingrix – GSK)
for prevention of herpes zoster (shingles) in adults ≥50
years old. Shingrix is the second herpes zoster vaccine
to be approved in the US;...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.